Conditionally replicating adenoviruses are developing as a complement to traditional cancer therapies. Ad[I/PPT-E1A] is an E1B/E3-deleted virus that replicates exclusively in prostate cells, since the expression of E1A is controlled by the recombinant 1.4 kb prostate-specific PPT promoter. The transcriptional integrity of PPT is maintained by the 3.0 kb mouse H19 insulator that was introduced directly upstream of the PPT sequence. In order to increase the cloning capacity to be able to reintroduce E3 sequences in the 35.7 kb Ad[I/PPT-E1A] genome, various shorter insulators were examined in a luciferase reporter gene assay. It was found that the 1.6 kb core H19 insulator (i) improves the activity of PPT, compared to the 3.0 kb full-length insulator, while still maintaining prostate cell specificity and releasing 1.4 kb of space for insertion of additional sequences. To improve the ability of the virus to efficiently lyse infected cells and persist in vivo, we inserted the adenovirus death protein (ADP) or the full-length adenovirus E3 region. The oncolytic activity of PPT-E1A-based viruses was studied using MTS, crystal violet and replication assays. The virus with the reintroduced full-length E3-region (Ad[i/PPT-E1A, E3]) showed the highest cytopathic effects in vitro. Furthermore, this virus suppressed the growth of aggressively growing prostate tumors in vivo. Therefore, we conclude that Ad[i/PPT-E1A, E3] is a prostatespecific oncolytic adenovirus with a high potential for treating localized prostate cancer.
Introduction
Prostate cancer is the most common cancer among men in Europe and the United States, and the third most common cancer among men in the world. 1 The current therapies for localized prostate cancer are radical prostatectomy, external beam irradiation or brachytherapy. However, the risk for relapse is high and surrounding tissues are often injured during these procedures. There is no curative treatment for metastatic prostate cancer, but the growth of cancer cells can be suppressed by hormone withdrawal for up to 2 years until the cancer achieves androgen independence. 2 Conditionally replicating adenoviruses (CRAds) are developing as a complement to traditional cancer therapies. 3 These viruses replicate under certain conditions, for example in tumor cells or in certain cell types. Viral replication leads to cell death and an important advantage of CRAds as a cancer treatment is that every infected cell releases new infectious viruses that spread to surrounding tumor cells. 4 The adenoviral E1A gene is important for the activation of the viral gene expression cascade. Therefore, by controlling E1A expression with a tumor-or tissue-specific promoter, viral replication can be restricted to certain cell types. 5 Ad[I/PPT-E1A] is an E1B/E3-deleted adenovirus that replicates exclusively in normal and neoplastic prostate epithelial cells since the expression of E1A is controlled by the recombinant prostate-specific PPT sequence. 6, 7 The PPT sequence is composed of a prostate-specific antigen (PSA) enhancer, 8 a prostate-specific membrane antigen (PSMA) enhancer 9 and a T cell receptor g-chain alternate reading frame protein (TARP) promoter. 10 The PSMA enhancer, which upregulates PSMA expression in androgen-depleted prostate cancer cells, also ensures that the PPT sequence is active under androgen-deprived conditions. 6, 11 The mouse H19 insulator 12, 13 (I), with enhancer blocking activity, was placed upstream of PPT to protect it from interfering signals from the adenoviral backbone. 14 Proteins expressed by the adenoviral E3 region play a crucial role in blocking immune responses from the host and are important for the persistence of the viral infection. 15, 16 Furthermore, the 0.3 kb adenovirus death protein (ADP), located in the E3 region, is important for proper viral release from the infected cell. 17 Since the 35.7 kb Ad[I/PPT-E1A] virus is E3 deleted, we hypothesized that it could be improved by the reinsertion of E3 or ADP. However, in order to introduce the 2.7 kb full-length E3 region, we needed more cloning space (at least 0.6 kb) since a recombinant virus should not exceed 105% of the 36.0 kb wild-type (wt) Ad5 genome. 18 Therefore, two shorter insulators, the 1.2 kb chicken b-globin HS4 insulator 19 (HS4) and the 1.6 kb active region of the H19 insulator (i), have been investigated in parallel with the 3.0 kb full-length H19 insulator. The viruses were evaluated with regard to activity and specificity, and the short H19 insulator was found to be sufficient, thereby releasing 1.4 kb that was enough to insert the E3 region. Ad[i/PPT-E1A], Ad[i/PPT-E1A, E3] and Ad[i/PPT-E1A, ADP] were produced and compared to the original Ad[I/ PPT-E1A] virus. We found that Ad[i/PPT-E1A, E3] was the most effective virus for killing prostate cancer cells in vitro and suppressing the growth rate of a fast growing prostate cancer xenograft in vivo.
Materials and methods

Cell lines
The prostate adenocarcinoma LNCaP and the lung carcinoma A549 were purchased from ATCC, Rockville, MD. The prostate adenocarcinoma PC-346C was obtained from Dr C Bangma, Erasmus University, Rotterdam, the Netherlands. The colon carcinoma HT-29 and the glioma U343 were obtained from Dr J Carlsson, Uppsala University, Uppsala, Sweden. The transformed embryonic retina 911 was purchased from Crucell, Leiden, the Netherlands. The human foreskin fibroblast 1064SK was obtained from Dr NE Heldin, Uppsala University, Uppsala, Sweden. The hepatocellular carcinoma HepG2 and the breast adenocarcinoma T47D were obtained from Dr N Maitland, York University, York, United Kingdom. The breast adenocarcinoma ZR-75-1 was obtained from Dr J Bergh, Karolinska Institute, Stockholm, Sweden. The melanomas 397mel and 526mel were obtained from Dr T Boon, Ludwig Institute for Cancer Research (LICR), Brussels, Belgium. The embryonic kidney 293T was obtained from Dr J Ericsson, LICR, Uppsala, Sweden. LNCaP, A549, HT-29 and U343 were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (hepes) and 1 mM sodium pyruvate. PC-346C was cultured in Dulbecco's modified Eagle's medium (DMEM):F-12 supplemented with 2% FBS, 0.01% bovine serum albumin, 10 mg ml À1 epidermal growth factor (Sigma-Aldrich, St Louis, MO), 1% insulintransferrin-selenium, 0.1 nM R1881 (NEN Life Science Products Inc., Boston, MA), 1.4 mM hydrocortisone (Sigma-Aldrich), 0.6 ng ml À1 triiodothyronine (SigmaAldrich), 0.1 mM phosphoethanolamine, 50 ng ml À1 cholera toxin (Sigma-Aldrich), 0.1 mg ml À1 fibronectin (SigmaAldrich) and 20 mg ml À1 fetuin (Sigma-Aldrich). 911, 1064SK, HepG2, T47D, ZR-75-1 and 293T were cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine and 1 mM sodium pyruvate. 397mel and 526mel were cultured in Iscove's modified Dulbecco's medium supplemented with 10% FBS and 3.2 mM L-glutamine. All cell culture reagents were from Invitrogen (Carlsbad, CA) except when stated otherwise.
Recombinant adenoviral vectors
Recombinant adenoviruses were constructed using the AdEasy system. 20 The original pAdEasy1 and pShuttle vectors were kind gifts from Dr B Vogelstein (Johns Hopkins, Baltimore, MD). The pShuttle-I/PPT-E1A and pShuttle-I/PPT-LUC vectors containing the 3 kb large mouse H19 insulator (I), the 1.4 kb recombinant human PPT promoter and either the 1.1 kb E1A sequence from adenovirus serotype 2 or the 1.9 kb luciferase (LUC)/ polyA sequence have been described earlier. 6, 7 New shuttle vectors. The 1.6 kb mouse H19 core insulator (i) was PCR amplified from pShuttle-I/PPT using the Expand high-fidelity enzyme mix (Roche, Mannheim, Germany) and the following primers: GCGG CCGCGATCATGGAATGTATTGCAG (smallH19.F1) and GGTACCTTACCTGGGACATTGCAATG (small H19.R1). The PCR product was T/A cloned into pCR2.1 (Invitrogen) and sequenced (BigDye, Perkin Elmer, Norwalk, CT). The large H19 insulator, containing both the core and a spacer, was removed from the pShuttle-I/PPT-E1A and pShuttle-I/PPT-LUC vectors using KpnI and NotI and replaced with the smaller core insulator to generate pShuttle-i/PPT-E1A and pShuttle-i/PPT-LUC, respectively. The 1.2 kb 5 0 -HS4 chicken b-globin insulator was excised from pJC13-1 (a kind gift from Dr G Felsenfeld, National Institutes of Health, Bethesda, MD) using KpnI and subcloned into pShuttle-PPT-LUC to generate pShuttle-HS4/PPT-LUC. The correct orientation was verified by DNA sequencing.
New backbone vectors. The pAdEasy(E3) and pAdEasy (ADP) adenoviral backbone plasmids were generated by a number of subclonings. First, pAdEasy1, which lacks E3, was digested with SpeI and BamHI and the 6230 bp fragment containing the DE3 flanking sequences was gel purified and inserted into pBluescript II SK (Stratagene, La Jolla, CA) to generate pBlue(6230). Wild-type adenovirus serotype 5 (Ad5 wt) DNA (a kind gift from Dr G Akusja¨rvi, Uppsala University, Uppsala, Sweden) was digested with SpeI and NdeI and the 4008 bp fragment, containing the E3 region, was gel purified and inserted into pBlue(6230) to generate pBlue(E3). pAdEasy1 and pBlue(E3) were then digested with PacI and SpeI (unique sites) so that the 8890 bp insert from pBlue(E3) could be subcloned into the 27230 bp backbone from pAdEasy1 to generate pAdEasy(E3). The ADP sequence was PCR amplified from Ad5 wt DNA using the following primers: AATAAATTATAAATGACCAA CACAACCAACGCGGCC (ADP.F1, which introduced a polyA signal and an in frame stop codon in front of the start codon) and CTCTTATAATCATACTGTAAGA GAAAAGAACATGTG (ADP.R1). The PCR product was T/A cloned and sequenced to generate pCR2.1(ADP). pBlue(6230) was digested with EcoRI and NdeI, and the 1100 bp fragment containing the DE3 flanking sequence was gel purified and inserted into 2 (DakoCytomation, Glostrup, Denmark) diluted 1:100 in PBS. After 2 h of light-protected incubation at RT, the cells were washed twice in PBS and green cells were counted using an inverted phase contrast microscope with a fluorescence illuminator (Olympus, CK40). The viruses were stored in aliquots at À80 1C. 6 The MOIs were 10 FFU per cell for PC-346C and U343; 50 FFU per cell for LNCaP, 1064SK, 397mel, HepG2, T47D and ZR-75-1; and 100 FFU per cell for 526mel and HT-29. After transduction, the cells were cultured for 48 h and lysed (25 mM Tris-phosphate, 2 mM dithiothreitol, 2 mM 1,2-cyclohexanediaminetetraacetic acid (CDTA), 10% glycerol, 1% Triton X-100). LUC activities were measured in triplicate samples according to the manufacturers' suggestions (Pharmingen, San Diego, CA) using a Wallac VICTOR 2 multilabel counter (PerkinElmer, Turku, Finland). Protein concentrations were measured using Coomassie Plus Protein Assay Reagent (Pierce, Rockford, IL). The background levels (LUC activity in untransduced cells) were subtracted. LUC activity is presented as relative luciferase units (RLU) per mg protein or expressed in relation to Ad[CMV-LUC].
Western blot LNCaP cells were transduced with Ad
and Ad5 wt at an MOI of 10 FFU per cell. Cells were harvested 24, 48 and 72 h after transduction and protein extracts were prepared. Lysis buffer and protein concentration measurements have been described earlier. 7 The protein samples were separated on 15% SDS-polyacrylamide gel electrophoresis (PAGE) gels and then transferred to polyvinylidene fluoride-membranes (Bio-Rad, Hercules, CA). The membranes were incubated with a rabbit polyclonal antiserum against ADP (1:1600, a kind gift from Dr A Tollefson and Dr W Wold, St Louis University, St Louis, MO), 21 a mouse monoclonal anti-E1A antibody (1:1000, M73, Neomarkers Inc, Fremont, CA) or a goat polyclonal anti-b-actin antibody (1:1000, I-19, Santa Cruz Biotechnology, Santa Cruz, CA). Peroxidase (POD)-conjugated anti-mouse/rabbit (1:10000; Roche) and horseradish peroxidase (HRP)-conjugated donkey anti-goat (1:5000; Santa Cruz) were used as secondary antibodies. BM Chemiluminescence Western Blotting kit (Roche) was used to visualize blots with the POD-conjugated antibody and the Western Blotting Luminol Reagent (Santa Cruz) was used for blots with the HRP-conjugated antibody. or Ad5 wt. Cells were harvested 72 h after transduction, and cell lysates were prepared by four cycles of freezing and thawing. Viral titers in the cell lysates were determined using the FFU assay using serial dilutions of the lysates. Replication was defined as the titer at 72 h and expressed in relation to Ad5 wt replication.
Cell viability assay
Luciferase-expressing tumor cells
A retroviral vector expressing both firefly LUC and enhanced green fluorescent protein (GFP) was constructed as follows. The 1.65 kb LUC sequence was PCR amplified from pGL3Basic (Promega) using the following primers: GTACTCGAGCCATGGAAGACG CCAAAAAC (luciferase.F-XhoI) and GCGGCCGCTC TAGAATTACACGGCGATC (luciferase.R-NotI). The PCR product was T/A cloned into pCR2.1 and sequenced to verify its integrity. The LUC sequence was then subcloned into the retroviral pBMN-I-GFP plasmid (a kind gift from Dr G Nolan, Stanford University, Palo Alto, CA), upstream of the internal ribosome entry site using XhoI and NotI to generate pBMN-LUC-I-GFP. All transformations using retroviral plasmids were performed in Stbl-2 bacterial cells (Invitrogen). The 293T cell line was transfected with pBMN-LUC-I-GFP together with gag-pol-and Rd114 envelope-containing plasmids (kind gifts from Dr A Loskog, Uppsala University, Uppsala, Sweden) using Novagen's GeneJuice transfection reagent (Merck Biosciences, Nottingham, UK). Retroviral supernatants were collected after 48-72 h.
A LUC-and GFP-expressing LNCaP cell line, LNCa-P(LUC/GFP), was produced as follows. LNCaP cells (1-2 Â 10 5 cells per well in a six-well plate) were infected through spinoculation with 2-3 ml retroviral supernatant together with 4 mg ml À1 polybrene (Sigma-Aldrich). After 48 h, the GFP-positive cell fraction, B15% of the cells, were sorted by flow cytometry (FACSVantage DiVa Turbo Sorter, BD Biosciences, San Diego, CA), expanded and stored in liquid nitrogen.
Animal studies
Animals. Male, 4-week old, C57/BL/6 Nu/Nu mice were purchased from M&B (Ry, Denmark). The animals were housed at the Rudbeck animal facility (Uppsala, Sweden) in individually ventilated cages (three mice per cage). The mice were acclimated for 1 week before tumor implantation. The studies were approved by the animal ethics committee in Uppsala (C67/4). ).
Statistical analysis
Statistical comparison was done using the GraphPad Prism program (GraphPad Software, San Diego, CA). One-way analysis of variance followed by Bonferroni's multiple comparison test was used to compare the LUC activity between viruses with different insulators. The two-tailed Mann-Whitney test was used to compare the growth rate between LNCaP and LNCaP(LUC/GFP) cells in mice. The logrank test was used to compare survival curves created using Kaplan-Meier.
Results
The core H19 insulator improves the activity of the prostate-specific PPT promoter Ad[I/PPT-E1A] is an E1B/E3-deleted adenovirus that replicates exclusively in normal and neoplastic prostate after 24 h for Ad5 wt and one band for the PPT-E1A-based viruses. The ADP protein was expressed after 24 h in Ad[i/PPT-E1A, ADP]-infected cells, verifying that ADP expression in this case is primarily controlled by the early native E3 promoter. Expression of the ADP protein in Ad[i/PPT-E1A, E3]-and Ad5 wt-infected cells was detectable after 48 h, verifying that ADP expression is primarily controlled by the adenoviral major late promoter in these viruses. The data confirmed that the reinserted ADP and E3 sequences were functional and located in the correct positions within the adenoviral genome. Figure 5c ). An example of in vivo detection of the LUC activity of LNCaP(LUC/GFP) tumors in two mice treated with Ad[i/PPT-E1A, E3] and PBS, respectively is displayed in Figure 5d .
PPT-based viruses kill prostate cancer cells effectively
Discussion
The first generation adenoviral vectors are deleted in the E1 and E3 regions. The E1 genes are deleted to make them replication defective, and E1 proteins must then be provided in trans by the packaging cells. The E3 genes are removed to increase the transgene cloning capacity, since E3 proteins are not needed to produce adenoviral vectors in cell culture systems. Proteins expressed from the E3 region are important for deviation of the host immune response. The ADP, which is also located in the E3 region but expressed primarily during the late stage of infection, is important for efficient cell lysis and viral release. Therefore, to improve the longevity of adenoviruses in vivo, the E3 region may be reintroduced. Ad[I/PPT-E1A] is a CRAd that replicates only in prostate cells of epithelial origin, including prostate adenocarcinoma cells, since E1A is controlled by the recombinant prostate-specific promoter PPT. 7 In this study, Ad[I/PPT-E1A] has been modified to increase its persistence in vivo. First, the full-length H19 insulator upstream of the PPT promoter was exchanged for a shorter insulator because the cloning capacity of the vector was close to its limit. In LUC reporter gene assays using Ad[PPT-LUC]-based vectors, we found that the HS4 insulator was as good as the full-length H19 insulator at protecting the PPT promoter from transcription-repressing signals from the upstream left inverted terminal repeat (LITR)/packaging sequence/E1A enhancer. In addition, we repeatedly found that the short (core) H19 insulator (i) containing the active insulating part of H19 was in fact better than the full-length H19 (core and spacer) insulator (I) at protecting the PPT promoter in the adenovirus environment. Furthermore, the specificity of the PPT promoter was not compromised when using the short compared to the full-length H19 insulator, and if anything, i/PPT appeared even more prostate specific. The reason is not completely understood, however, it is known that the distance between the insulating elements in H19 and the enhancer sequence upon which it acts is of importance. Ginjala et al. have reported that multiple cis elements within the H19 insulator domain organize a distance-dependent silencer. 13 The short H19 insulator lacks the spacer domain, which faces the LITR/E1A enhancer in the large H19 insulator. Therefore, the distance between the H19 core and LITR/packaging/ E1A enhancer sequence, which the H19 cis elements act upon, is different. The distance between the H19 core and PPT promoter is identical for the short and full-length H19 insulator. Taken together, this may contribute to the positive effects observed when using the short H19 insulator. In nonprostate cells the activity was at background levels with one exception, in HepG2, where the activity of the PPT-based vectors was somewhat higher. This may be due to HepG2 being more easily transduced. However, Ad[i/PPT-LUC] was still able to maintain the integrity of the promoter and compared to Ad[CMV-LUC], it is obvious that the activities of the PPT-based viruses are low even in HepG2. Therefore, we constructed the next generation of PPT-controlled oncolytic viruses with the core H19 insulator (i).
Three new PPT-E1A-based oncolytic adenoviruses were constructed with the core H19 insulator and E1B deletion. 24, 25 The precise reasons for this in vitro advantage is currently not known. However, it may be due to ADP expression late in the virus cycle and/or enhancement of infectivity via the integrin-binding RGD motif.
24 E3 proteins are believed to be of importance in vivo to protect the infected cells from immune system recognition, thereby leading to efficient infiltration within the tumor. 5, 15, 16 Furthermore, it is known that adenovirus E3 proteins can protect transplanted cells from immune system recognition and thereby prolong transplants of human cells in immune competent mice. 26 Herein, two new adenoviral backbone vectors adapted for the AdEasy system have been constructed: one containing the full-length E3 region and one with the ADP sequence inserted in the E3-deleted region. These backbone vectors make it easier to produce new adenoviral vectors for future in vivo studies.
To study the new viruses in vivo, a derivative of the prostate cancer cell line LNCaP was produced using a retrovirus with an expression cassette containing both GFP and LUC. However, during the transformation process the cells grew rapidly in vitro and tumors from these cells grew very aggressively in vivo. This could be due to the expression cassette integrating close to an oncogene or suppressor gene, and that these cells acquired a growth advantage. The tumor take of LNCaP(LUC/ GFP) was 100% when as little as 1.5 Â 10 5 cells were E3 enhances efficacy of an oncolytic adenovirus A Danielsson et al grafted, compared to nonmodified LNCaP that did not have more than 50% tumor take even when 4 Â 10 6 cells were grafted. Tumor growth was followed by bioluminescence imaging and caliper measurements. The in vivo imaging provides real-time measurements because of the rapid conversion of the LUC enzyme. 27 A large, fast growing tumor can consist of necrotic material as new vessels do not have time to develop. In contrast to tumor size measurements, the LUC signal is directly correlated to the amount of metabolically active cells. 28 Because LNCaP(LUC/GFP) tumors grew so aggressively, it was difficult to detect clear differences between the viruses when treating tumor-bearing mice. However, a small delay in tumor growth could be observed in mice treated with either of the viruses compared to the control group of PBS-treated mice. The group of mice treated with Ad[i/PPT-E1A, E3] had the highest tumor growth suppression. There was a significant prolonged survival for mice treated with Ad[i/PPT-E1A, E3] compared to the control group of PBS-treated mice. We believe that the relatively small delay in tumor growth observed in the in vivo experiment was a consequence of the fast growing LNCaP(LUC/GFP) tumor model. We attempted to use normal LNCaP cells as a tumor model as well, however, the tumor take was uneven and low. Since we evaluated several viruses in parallel and wanted to include at least seven mice per group, we were unable to use normal LNCaP cells in our in vivo model. Based on our in vitro and in vivo findings, we conclude that Ad[i/PPT-E1A, E3] is the most promising PPT-based virus for treatment of localized prostate cancer.
